Milrinon Hikma (Milrinone)

Milrinone, the active ingredient in Milrinon Hikma, is a phosphodiesterase 3 inhibitor presented as an intravenous solution for injection use. It is employed to improve cardiac output in patients with acute decompensated heart failure and cardiogenic shock, typically in a hospital setting.

GNH USA supplies Milrinon Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone acts as an inotropic agent for severe cardiac conditions, enhancing contractility and reducing vascular resistance.

Acute decompensated heart failure: increases cardiac output and relieves symptoms of low‑output state. Cardiogenic shock: provides rapid hemodynamic support to stabilize blood pressure. Post‑cardiac surgery low‑output syndrome: improves myocardial contractility when conventional therapy is insufficient.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension - Tachyarrhythmias - Headache - Nausea - Flushing - Tachycardia

Serious or Rare Side Effects: - Severe hypotension requiring intervention - Ventricular arrhythmias - Myocardial ischemia - Thrombocytopenia - Anaphylactic or severe allergic reactions

Milrinone requires careful monitoring and specific safety measures before and during therapy.

Hemodynamic monitoring: continuous blood pressure and ECG observation are essential. Renal impairment: assess renal function and adjust dosing as needed. Electrolyte disturbances: correct potassium and magnesium levels prior to infusion. Concomitant vasodilators: may amplify hypotensive effects. Recent myocardial infarction: use with caution due to increased ischemic risk. Store at ambient temperature: keep in original container, protect from light and moisture.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase inhibitors: risk of profound hypotension. - Potent vasodilators (e.g., nitroprusside): may cause severe blood pressure drops. - Strong CYP3A4 inhibitors: increase plasma concentrations of milrinone.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may diminish inotropic response. - Diuretics: can exacerbate electrolyte imbalances. - Anticoagulants: monitor for bleeding if hypotension occurs.